Amgen Shares Trimmed by CSM Advisors

Institutional investor reduces stake in biotech giant

Mar. 17, 2026 at 8:19am

Got story updates? Submit your updates here. ›

CSM Advisors LLC, a financial advisory firm, has trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 52.2% during the third quarter, according to a recent SEC filing. The firm now owns 6,304 shares of the medical research company's stock, down from 13,187 shares previously.

Why it matters

Amgen is one of the world's largest biotechnology companies, known for developing innovative therapies for serious illnesses. Changes in institutional ownership can signal shifts in investor sentiment and market expectations around the company's performance and future prospects.

The details

According to the 13F filing, CSM Advisors sold 6,883 shares of Amgen stock during the third quarter, reducing its total position to 6,304 shares valued at $1.778 million. The move comes as Amgen's stock price has fluctuated in recent months, with the share price ranging from a low of $261.43 to a high of $391.29 over the past year.

  • CSM Advisors trimmed its Amgen holdings during the third quarter of 2026.

The players

CSM Advisors LLC

A financial advisory firm that has reduced its stake in Amgen Inc.

Amgen Inc.

A global biotechnology company that develops innovative therapies for serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The reduction in CSM Advisors' Amgen holdings suggests a potential shift in investor sentiment around the biotech company, though the overall reasons behind the move are not entirely clear from the limited information provided. Amgen's stock performance and market positioning will continue to be closely watched by investors and analysts.